Proteomics International Unveils PromarkerEso: A Breakthrough in Esophageal Cancer Diagnosis

Proteomics International Laboratories Ltd. ( (AU:PIQ) ) just unveiled an update.

Proteomics International Laboratories Ltd has announced the publication of clinical validation results for its PromarkerEso blood test, which diagnoses esophageal adenocarcinoma with high accuracy. This test, which offers a non-invasive alternative to current endoscopy procedures, demonstrated 91.4% sensitivity and 98.9% specificity, marking a significant advancement in early detection of this cancer. The commercialization of PromarkerEso is expected to begin in Australia, with plans to expand to other regions. This development could revolutionize the management of esophageal cancer, potentially improving early diagnosis rates and health outcomes for patients globally.

The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

More about Proteomics International Laboratories Ltd.

Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on developing non-invasive diagnostic solutions. The company is known for its innovative serum glycoprotein biomarker-based tests, with a market focus on improving early detection and management of diseases such as esophageal adenocarcinoma.

Average Trading Volume: 148,180

Technical Sentiment Signal: Sell

Current Market Cap: A$59.56M

See more data about PIQ stock on TipRanks’ Stock Analysis page.